First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.

Overview of attention for article published in Cancer Discovery, November 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 14 news outlets
blogs: 1 blog

twitter: 25 X users
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 10 Mendeley

Summary News Blogs X Wikipedia Dimensions citations

So far, Altmetric has seen 1 blog post.

First in Human Trial of New Drug Raises Hopes for Patients with Relapsed Blood Cancer

Global Health News Wire, 07 Nov 2023

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.